Must be special: BEBT-701 clinical trial application approved by the National Medical Products Administration.

Bo Beit Announcement: Recently, the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company's independently developed global first-in-class AGT/PCSK9 dual-target small interfering nucleic acid drug BEBT-701 for the treatment of mild to moderate hypertension combined with elevated low-density lipoprotein cholesterol Phase I-II clinical trials.